For FDA-approved GLP-1 medications, contraindications include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and a history of severe allergic reaction to the drug
Its prescribed for adults with obesity (BMI 30 kg/m) or those who are overweight (BMI 27 kg/m) with at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia
participated in the advisory boards of Biogen MA Inc., Roche and Eli Lilly
Sterile glass vials reduce the chance of contamination, thus ensuring that peptides remain accurate for scientific research
Conversely, no significant differences in type 2 inflammatory markers were observed between treatment with a GLP-1R/GIPR dual agonist and single GLP-1R or GIPR agonists [189]
Brignati represented Novo Nordisk in the patent filing